Stocks · News reference

Kamada Announces CFO Chaime Orlev To Depart Effective December 31 To Pursue Other Opportunities; Successor Search Underway

Aug 12, 2026, 11:08 AMBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaOct 6, 2026, 11:06 AMBenzinga Newsdesk
Kamada Expands Biosimilar Portfolio With Commercial Launch Of Two Additional New Products In Israel, Adding To Existing Portfolio Of Two Products
Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA))), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today
KMDA
Globenewswire IncSep 10, 2026, 11:00 AMNa
Kamada to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Kamada Ltd., a global biopharmaceutical company specializing in plasma-derived therapies, announced that CEO Amir London will present at the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026. The presentation will be webcast and available for 30 days. The company continues to focus on organic growth of its commercial portfolio, plasma collection operations, and pursuing M&A opportunities.
KMDA
BenzingaAug 12, 2026, 11:07 AMBenzinga Newsdesk
Kamada Affirms FY2026 Sales Guidance of $200.000M-$205.000M vs $202.048M Est
Kamada (NASDAQ:KMDA) affirms FY2026 sales outlook from $200.000 million-$205.000 million to $200.000 million-$205.000 million vs $202.048 million estimate.
KMDA